Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Needham & Company Downgrades Lexicon Pharmaceuticals (LXRX) to Hold
February 23, 2018 7:14 AM ESTNeedham & Company downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold.
Analsyt Alan Carr commented, "Lexicon reported $5.4M U.S. Xermelo 4Q17 sales (+3% q/q), below our and consensus $7.5M ests. Challenges include low number of patient starts and a large number... More
Lexicon Pharmaceuticals (LXRX) PT Lowered to $25 at Stifel; 'Despite Slow Xermelo Progress, We Still Can’t Reconcile Valuation Here'
February 22, 2018 5:20 PM ESTStifel lowered its price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $25.00 (from $27.00) while maintaining a Buy rating.
... More